NVAX stock: Here’s what to expect when Covid shot-maker Novavax reports

Novavax (NVAX) is expected to report tapering losses and double-digit sales growth for the fourth quarter late Tuesday. Ahead of the report, NVAX stock rose sharply.

X

The company makes a Covid vaccine called Nuvaxovid. In the US, it is legal for those ages 12 and older as the primary recording series. The Food and Drug Administration has also approved Nuvaxovid as a booster vaccine for adults.

Novavax’s fourth-quarter results should paint a clear picture of the future of U.S. vaccines. Pfizer and Moderna’s Covid shots posted small sales gains in 2022, although sales are expected to fall this year. However, it is important to note that Novavax uses a different method to vaccinate patients. While Pfizer and Moderna’s recordings rely on messenger RNA platforms, Novavax’s recording is DNA-based.

In early trading today, NVAX shares are up 4.8% near the 9.10.

NVAX stock: Lower losses expected

Analysts polled by FactSet expect Novavax to report a loss per share of $1.01, down from a loss of $11.18 per share in the year-ago period. They’re also calling for revenue of $383 million, up almost 73% year over year.

The company’s outlook is also important. NVAX equity analysts are forecasting losses of $4.99 per share in 2023, down from an estimated 2022 loss of $7.16 per share. But they also expect sales to decline this year, reaching $1.26 billion, versus $2.01 billion forecast for 2022.

That would be in line with the expectations of Pfizer and Moderna. Both companies expect sales of their Covid vaccines to decline in 2023. Vaccination is slowing and the US public health emergency is now set to end in May.

Meanwhile, NVAX stock has the worst possible Relative Strength Rating of 1. This places the stock in the lowest 1% of all stocks when it comes to 12-month performance, according to IBD Digital.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

YOU MAY ALSO LIKE:

“Here We Go Again”: Seagen rises as Pfizer reportedly mulls an acquisition

Reata stock plummets as official’s exit rocks FDA neuroscience division

Looking for the next big stock market winners? Get started with these 3 steps

Find the best long-term investments with IBD Long-Term Leaders

Run custom stock screens with MarketSmith